CHICAGO, May 15, 2025--(BUSINESS WIRE)--MAIA Biotechnology ... data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American ...

As of the cut-off date of April 2, 2025, a total of 21 patients had been enrolled and received at least one dose of PAS-004 in six cohorts (Capsules: 2mg, 4mg, 8mg, 15mg, 22mg / Tablets: 4mg). The ...

An oral presentation at ASCO & EHA Congress from the CARTITUDE-1 study highlighting heavily pre-treated patients that remain ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses New ...

About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of ...

Poster presentation to highlight the ongoing global Phase 3 ASP-1929-381 study at ASCO 2025 ; Global patient enrollment continues, with Taiwan now actively e ...

Finance Income, net was $1.0 million for the three months ended March 31, 2025, compared to $0.7 million in the same period ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

Oncolytics Biotech® Inc. shares T.ONC are trading unchanged at $0.56.

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today shared the ...

These abstracts summarize Versamune ® HPV (PDS0101) studies to be presented during the Head and Neck Cancer Poster Session taking place May 30-June 3, 2025, in Chicago, Illinois. Kirk Shepard, M.D., ...